Essentials to Deliver Quality Care for Patients With CML: A Team Approach
  • CME
  • CE

Review this module by Jorge Cortes, MD, discussing optimal approaches to current treatment of patients with chronic-phase or acute-phase CML.
Jorge Cortes, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: March 1, 2022 Expiration: February 28, 2023

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Manage treatment-related toxicities, such as GI or cardiac toxicities, associated with use of TKIs in patients with CML to maintain the correct dose and expand treatment options
  • Increase patient involvement in the initiation of treatment, monitoring of response, managing toxicity, and optimizing adherence
  • Select individualized frontline therapy for patients with chronic-phase CML, considering patient age, medical history and comorbidities, and risk score (Sokal or Euro score)
  • Monitor first-line treatment responses and determine optimal timing of therapy changes
  • Evaluate the available evidence, potential predictive factors, patient preferences, and expert recommendations guiding potential therapy discontinuation and treatment-free remissions
  • Plan second-line, third-line, and later therapeutic strategies to manage resistance after previous TKI failure
  • Describe research to increase the number of patients able to discontinue treatment through combination of TKIs with novel agents

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Novartis Pharmaceuticals Corporation
Pfizer, Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Jorge Cortes, MD

Director, Georgia Cancer Center
Eminent Scholar, Georgia Research Academy
Augusta, Georgia

Jorge Cortes, MD, has disclosed that he has received funds for research support and consulting fees from Bio-Path Holdings, Novartis, Pfizer, Sun Pharma and Takeda.

Staff

Jerfiz Constanzo, PhD, MBA
Scientific Director
Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Kristi Kay Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Orbaugh, RN, MSN, RNP, AOCN, has received speaker fees from BMS, Lilly, Regeneron, Gilead, Morphosys, Pfizer, AstraZeneca, and DSI.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with CML.

Goal

The goal of this activity is to improve the competence of all members of the interdisciplinary team in applying the latest guidance and clinical data in the management of individuals with chronic myeloid leukemia.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-067-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 01, 2022, through February 28, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Downloadable slideset with highlights from key hematologic cancers as presented at EHA 2022 Congress, from Clinical Care Options (CCO)

Stéphane de Botton, MD Jesús F. San-Miguel, MD, PhD Alessandra Tedeschi, MD Released: June 30, 2022

Experts discuss important new data from ASCO 2022 that may impact treatment for chronic lymphocytic leukemia and mantle cell lymphoma, from Clinical Care Options (CCO)

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: June 30, 2022

From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy into community care

Jesús G. Berdeja, MD Caron A. Jacobson, MD Released: June 30, 2022

Slides from Clinical Care Options (CCO) with key findings on BTK inhibitors in CLL and MCL from the 2022 ASCO, EHA, Pan Pacific, ESMO, and SOHO meetings

Released: June 27, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings